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This European Neuromuscular Centre (ENMC) care
workshop was attended by 19 professionals working in
the ﬁeld of neuromuscular disorders (pediatric and adult),
pain or fatigue from 8 diﬀerent countries (USA, Great
Britain, Germany, France, Italy, Sweden, Denmark and
the Netherlands), and 3 patient representatives coming
from the Netherlands. This ENMC organized workshop
aimed to achieve consensus on the deﬁnition of pain and
fatigue in NMD, to deﬁne a core set of measurement
instruments for pain and fatigue in NMD, and to discuss
possible interventions. Prior to the workshop, all
participants received a questionnaire on the assessment
instruments and interventions that they regularly used to,
respectively, assess and treat pain and fatigue. Two
experts on (chronic) pain and fatigue in general (Henrie¨t
van Middendorp and Hans Knoop) were invited to
present an overview of deﬁnitions, mechanisms, and
measurement instruments for pain and fatigue. Next to
that, several participants presented data on the
prevalence of pain and fatigue in the various NMD
populations. Through group discussions with all
participants, consensus was reached on the deﬁnition and
core set of measurement instruments (to be used)/for use
in future research and clinical practice in NMD.0960-8966  2013 The Authors. Published by Elsevier B.V.
http://dx.doi.org/10.1016/j.nmd.2013.06.370
⇑ Corresponding author. Tel.: +31 24 3614892; fax: +31 24 3619839.
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Open access under C2. Background
Pain and fatigue are common symptoms in
neuromuscular disorders (NMD) with a prevalence of
30–90%, present in all types of NMD, both in adults and
children [1–6]. Pain and fatigue have a strong impact on
many activities of daily life, including mobility, work,
school, leisure, and sleep [4,7]. The diﬀerences in reported
prevalence could be due to diﬀerent deﬁnitions of pain
and fatigue, and various types of measurements. In order
to develop eﬀective treatment approaches, both
deﬁnitions and methods to measure pain and fatigue
should be agreed on.
3. Questionnaires
Questionnaires were sent to all participants prior to the
workshop to get an overview of the questionnaires on pain
and fatigue that are currently used in research and practice
in NMD [8]. In addition, the various interventions used to
treat pain and fatigue were investigated. To assess pain in
adults, nearly all participants used the SF-36 (items
related to pain), a Likert scale, visual analog scale
(=VAS), numeric rating scale (=NRS), and the McGill
Pain Questionnaire. For neuropathic pain, more speciﬁc
scales were mentioned, such as the Douleur Neuropathic
4 (=DN4), Neuropathic Pain Symptom Inventory
(=NPSI), or ID-pain. In children, all used the VAS or
the Faces Pain Scale (of which there are many diﬀerent
versions), few used body images to indicate the site of
pain or the PedsQol (pain items), and one used the San
Salvadour scale for severely handicapped children or the
Douleur Enfant Gustav Roussy Scale for children
between 2 and 6 years of age.C BY-NC-SA license.
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Fatigue Severity Scale (=FSS), Borg CR-10 scale, NRS
for fatigue, and some used the Modiﬁed Fatigue Impact
Scale or the Checklist Individual Strength (=CIS).
Speciﬁc for Myotonic Dystrophy type 1 (DM1), the
following sleepiness scales were reported: Daytime
Sleepiness Scale (DSS), Pittsburgh Sleep Quality Index
(PSQI), Epworth Sleepiness Scale (ESS), and Unnalinna
Narcolepsy Scale (UNS). For children, the (modiﬁed)
Borg scales were reported and the six minute walking test
for ambulant children.
As possible interventions for pain, all participants
mentioned guidance and advice for daily activities with
special attention for overuse, physical therapy, and
possible drugs such as pregabalin, citalopram, duloxetine,
amitriptyline, creatine monohydrate, and paminodrate.
For fatigue, possible interventions that were reported
included polysomnography to evaluate nocturnal
hypoventilation and treatment, guidance and advice for
daily activities with special attention for overuse, physical
therapy, and cognitive behavioral therapy. Only for DM1
drugs to treat sleepiness were mentioned such as
modaﬁnil, citalopram, and Ritalin.
The level of evidence for the eﬃcacy of the interventions
is low; available evidence is restricted to drug treatment for
neuropathic pain and sleepiness and fatigue in DM (see
Cochrane reviews).
4. Participants’ research on pain and fatigue in NMD
Baziel van Engelen reported on several studies in NMD
populations, consisting of cross-sectional data of adult DM
1 (n = 322), DM type 2 (n = 29), OculoPharyngeal
Muscular Dystrophy (OPMD) (n = 35), Chronic
Progressive External Ophthalmoplegia (CPEO) (n = 28),
FacioScapuloHumeral Dystrophy (FSHD) (n = 139), and
Charcot Marie Tooth (CMT) (n = 137), as well as
longitudinal data of adult DM1 (n = 79), FSHD (n = 65),
and CMT (n = 73). To assess pain and fatigue in these
studies, the McGill pain questionnaire and VAS were
used for pain, and the CIS and SF-36 for fatigue. The
reported fatigue was between 54% (OPMD) and 68%
(CPEO), with signiﬁcant impact on daily functioning.
The pain scores were between 47% (DM1) and 96%
(CPEO), with a diﬀerent distribution pattern for each
speciﬁc type of NMD. Pain scores were independent of
age, impairments, physical activity level, or muscle force.
The longitudinal study in FSHD (n = 60) and DM1
(N = 75) resulted in an FSH health status model and a
DM1 health status model. Pain and fatigue were main
determinants of health status in both diseases [7]. These
models enable to rationally develop treatment strategies
in FSHD and DM1 and form the starting point of the
study presented by Nicoline Voet: the protocol of the
FACTS-2-FSHD trial. In this recently ﬁnished study,
aerobic exercise training is compared to cognitivebehavior therapy (data currently in analysis). Pain and
fatigue are measured by CIS, VAS for pain, 6 min
walking test, and SF36.
Birgit Steﬀensen reported on a study of self-reported
pain and fatigue in patients with FSHD and their healthy
relatives or caregivers. The FSS and VAS were used to
assess fatigue; pain was measured on a 1–7 scale as
adapted from the FSS, by VAS, and by localization on a
body image. Pain and fatigue scores were signiﬁcantly
higher in patients than in healthy persons, there was no
statistical diﬀerence between patients who were still able
to walk and those who were not, and there was a
tendency towards higher pain and fatigue scores in
patients with less muscle strength.
Marie Kierkegaard reported the results of a cross-
sectional study on 70 persons with DM1. The ICF
checklist was used for self-rating of perceived pain.
Fatigue and excessive daytime sleepiness was evaluated
with the FSS and ESS, as well as with the ICF checklist.
Fatigue, daytime sleepiness and pain were rated as a
problem in 76%, 80% and 51%, respectively. The impact
of the cut-oﬀ level for fatigue and excessive sleepiness
when using the FSS and ESS was stressed. For example,
with a score equal or above 4 in FSS 52% are classiﬁed
as experiencing fatigue compared to 17% when a cut-oﬀ
score equal or above 5 is used.
Cornelia Kornblum discussed her study of 22 patients
with DM1, 22 with DM2, and 22 controls. The FSS,
DSS, ESS, PSQI, and UNS were used to assess fatigue
and sleepiness as part of a more extensive psychological
test set. DM1 showed more sleepiness and fatigue in all
measurements compared to the other groups; only the
mean KFSS-, DSS-, and PSQI-scores were above the cut-
oﬀ for pathological performing. The DM2-patients
showed more fatigue and a lower sleep quality (mean
KFSS- and PSQI-scores were above the cut-oﬀ for
pathological performing); no diﬀerences were found in
daytime sleepiness. DM1 and DM2 patients were both
more fatigued than healthy controls, and DM1 more
than DM2.
Luca Padua showed the results of a study in 392 patients
with peripheral nerve diseases, in which the Neuropathic
Pain Symptom Inventory (NPSI), VAS, ID-pain, and
DN4 were assessed. In 60% of the patients, the VAS-pain
was 3 or higher, and approximately 30% had a VAS of 5
or higher. On ID-pain and DN4, 50–60% had symptoms
of neuropathic pain. The NPSI showed no statistical
diﬀerence between the diﬀerent symptoms of neuropathic
pain, in which paraesthesias had the highest score. In
another study on 65 patients with FSHD, the SF-36,
VAS-pain, and ID-pain were assessed. According to the
ID-pain, 7% of the patients had very probable
neuropathic pain, 20% probable neuropathic pain, 24%
possible neuropathic pain, 33% no pain, and 16% joint
pain exclusively.
Bernard Wuyam showed the preliminary results of an
ongoing study on the assessment of neuromuscular
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muscular dystrophies and CMT, and the eﬀect of exercise.
Ulla Werlauﬀ showed results of studies on the
perception of pain and fatigue in persons with spinal
muscular atrophy (SMA) (52 persons: 7.8–72.6 years)
and congenital myopathies (95 persons: 5.5–75.2 years).
The PedsQoL (generic, speciﬁc), SF-36, Egen
classiﬁcation 2 scale, FSS, and Modiﬁed Fatigue
Impact Scale were used to measure pain and fatigue.
In congenital myopathies, pain was a problem in all
muscles (overload?) whereas in SMA-type 2 it was not,
or related to an event like surgery. In this study,
fatigue was a problem in congenital myopathies but
not in SMA. From her results, Ulla Werlauf concluded
that PedsQoL, SF-36 and Modiﬁed fatigue impact scale
were not very sensitive or conclusive. The
recommended scale would be the FSS.
Imelda de Groot showed results of former studies in
adults with SMA and ALS and an ongoing study in
DMD. In an open questionnaire study in 99 adult SMA-
patients, divided into two groups (SMA type1–2 and type
3), neck pain was most prevalent in both groups (38% in
SMA1-2, and 34% in SMA3); fatigue was reported in
64% in SMA3, in contrast to 34% in SMA1-2. In a study
in 74 persons with ALS, no correlations were found
between functional abilities (measured with ALS-FRS),
and pain or fatigue (measured with SF-36). In the
ongoing study in boys with DMD (N = 30) and training,
the preliminary results show that boys with DMD have
similar adaptations to physical exercise (heart rate and
EMG-adaptations) as healthy age-matched controls
(N = 99) and comparable subjective fatigue (measured by
OMNI scale), but that some boys can perceive/
experience fatigue in rest.
Yaacov Anziska showed preliminary results of two
studies: one study in children with NMD (7 with
myopathy/limb girdle muscular dystrophy, 9 with DMD,
3 with CMT, and 2 with myasthenia gravis; age range 5–
19 years). The Epworth Sleepiness Scale, the Vignos, and
Brooke ratings scales, the Children’s Depression
Inventory, and the PedsQoL 3.0 Neuromuscular Module
for Patients and Parents were used. Except for the
myopathy/DMD-group, there was no correlation between
PedsQL-scores of the patients and those of their parents.
There was evidence of mild abnormal mood disorders
and mild-moderate sleepiness. A study of 31 adults (5
patients with DM1-2, 14 LGMD, 5 CMT, 5 motor
neuron diseases, 2 myasthenia gravis) in which the SF-36
was used gave similar results.
Carole Be´rard showed results of a study in 22 boys
with DMD with pain and osteopenia (7 ambulant, and
15 non-ambulant). In 21 of the 22 boys, a moderate to
severe pain was measured with NRS, most of the boys
(21) experienced pain during physiotherapy; 11 also
spontaneously, 9 during the night and 5 (non-
ambulant) during transfers. There was no correlation
between the NRS-pain score and osteopenia.Anna-Karin Kroksmark shared some practical
experiences on pain and fatigue in children with DMD
from studies performed at her centre. In these studies,
PedsQoL, Multidimensional Fatigue Scale, Sleep quality
index, and questions about pain and tiredness were used.
Pain has an increasing interest in the network in Sweden
and a national survey is now being performed. Adapted
Faces scales were shown.
Caron Coleman showed her work on establishing how
to measure pain in children: one size does not ﬁt all! Due
to the diﬀerent developmental stages the following
measurements were recommended for clinical utility:
0–5 years and cognitive or learning diﬃculties-
observation and parent/caretaker report; 5–7 years-faces
and questions to child and parents regarding location,
frequency, quality (if possible) and impact on function;
8+ years-combination of faces/NRS and questions as
above; 13+ years Brief Pain Inventory/faces/NRS.
Heinz Jungbluth gave an overview of diﬀerent childhood
NMD in which exertial myalgia with or without
rhabdomyolysis is a common primary or secondary
feature. One of the open questions that need to be
addressed in future research is whether the diﬀerent
mechanisms underlying these features in distinct disorders
will require diﬀerent treatment approaches.
Marion Main shared some thoughts on pain and fatigue
in children with NMD. Pain can be caused by secondary
complications of the disorder, such as contractures,
cramps, muscle soreness etc. A warning was given that the
physiotherapist can be a cause of pain due to treatments
like stretching. She pointed at the lack of knowledge on
the topic of fatigue with regard to the role of weakness in
the development of fatigue and the important role of
exercise in the management of pain and fatigue.
Finally, Jo Auld gave advices on the psychometric
properties that outcome measures on pain and fatigue
should encompass.
5. Conclusions
Pain as well as fatigue are currently measured by various
methods and several NMDs have been studied so far. It
can be concluded that pain and fatigue are highly
prevalent and important problems, both in adults and
children. It is important to diﬀerentiate pain and fatigue
from sleepiness, depression, de-conditioning, and side
eﬀects of drugs. Speciﬁc types of pain and fatigue, related
to the underlying NMD and/or stage of the NMD can be
distinguished. These should be diﬀerentiated from
aspeciﬁc pain and fatigue, which are not primary related
to NMD.
Fatigue can have physiological features, such as loss of
voluntary force or endurance during exercise/activity
(both of peripheral and central origin). This type of
fatigue is activity-related. This aspect of fatigue is also
applicable for cognitive fatigue, deﬁned as a reduction in
cognitive performance over time.
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As presented by the experts on pain and fatigue, both
pain and fatigue are multidimensional concepts and
include the following aspects:
 Characteristics: acute or chronic (“long lasting”),
intensity, frequency, location, quality.
 Cause(s).
 Consequences or impact on: body function(s),
activities of daily life, and participation.
 Cognitive-behavioral factors (predisposing and/or
perpetuating).
The proposed deﬁnition of pain in NMD is from the
International Association of Study on Pain (IASP): pain
is an unpleasant sensory and emotional experience
associated with actual or potential tissue damage, or
described in terms of such damage.
Fatigue can have many deﬁnitions. The proposed one is:
experienced/subjective fatigue is lack of energy or the
existence of weakness or exhaustion – mentally,
physically or both.
7. Proposed measurement core-sets
Several instruments to measure pain and fatigue in
NMD were discussed with experts in the research ﬁeld
[8]. Two types of measurement core-sets are proposed:
one to use in daily practice and one for research purposes.
For pain the following core-sets are proposed:
Core-set (daily practice):
 Numeric Rating Scales (faces for children)/FLACC
in young children.
 Modiﬁed Brief Pain Inventory.
 Hospital Anxiety and Depression Scale (HADS).
 Pay attention to organic/biomechanical causes/
neuropathic pain (if the latter is suspected: use
ID-pain or DN4).
Research (extended screening):
 Pain Disability Index (PDI) or Brief Pain Inventory
(BPI).
 SF-36.
 HADS and/or Beck’s Depression Index (BDI).
 Cognitive-behavioral factors.
 In case of neuropathic pain, use ID-pain or NPSI.
For fatigue:
Core set (daily practice):
 NRS.
 Checklist Individual Strength (CIS) (norms, multiple
dimensions), or if CIS is not available fatigue severity
scale (FSS) (impact of fatigue).
 Look for organic/biomechanical causes/forced vital
capacity.Extended/research:
 Physical activity (e.g. actography, activlim).
 Disability scale (e.g. SIP, SF-36).
 Psychological distress (e.g. Hospital Anxiety and
Depression Scale).
 Sleep disturbances.
 Social support scale.
 Fatigue-related cognitions.
 Pain.
8. Future plans
This workshop only covers discussions and proposals
for deﬁnitions of pain and fatigue in NMD and the core
set of measurements for daily practice and research. The
management of pain and fatigue is still a point to discuss
in the future. It was decided to collaborate on the use of
the core-sets and share data with each other in order to
get more insight in the possible contributing factors of
pain and fatigue in NMD. Based on these results,
possible management approaches can be discussed in a
next workshop on Management of pain and fatigue in
NMD.
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